De novo design of miniprotein inhibitors of bacterial adhesins
In the authors' words
The rise of multidrug-resistant bacterial infections necessitates the discovery of novel antimicrobial strategies. Here, we show that protein design provides a generalizable means of generating new antimicrobials by neutralizing the function of bacterial adhesins, which are virulence factors critical in host-pathogen interactions. We de novo designed high-affinity miniprotein binders to FimH and Abp chaperone usher pili adhesins from uropathogenic Escherichia coli and Acinetobacter baumannii, respectively, which are implicated in mediating both uncomplicated and catheter-associated urinary tract infections (UTI) responsible for significant morbidity worldwide. The designed antagonists have high specificity and stability, disrupt bacterial recognition of host receptors, block biofilm formation, and are effective in treating and preventing murine models of uncomplicated and catheter-associated UTIs in vivo. Here, the authors show that protein design is a generalizable strategy to generate new antimicrobials by neutralizing the function of bacterial adhesins to combat two causative agents of urinary tract infections, E. coli and A. baumannii.
In plain words AI summary
The researchers designed small proteins that bind tightly to two bacterial adhesins from E. coli and A. baumannii. These adhesins help bacteria cause urinary tract infections. The designed miniproteins are specific, stable, and block bacteria from recognizing host cells and forming biofilms. They worked in mice to treat and prevent both simple and catheter-associated urinary tract infections.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.
Appeared: Sunday, October 11. Nature Communications. Peer-reviewed journal.